ImMucin™ which targets the SP domain of the MUC1 cancer antigen. According to the National Cancer Institute, MUC1 is the second most promising cancer antigen, and it is expressed by over 90% of tumor types. MUC1 has therefore been heavily targeted, but with little success to date. Vaxil however, has developed its VaxHitTM immunotherapy platform specifically in order to target antigens like MUC1 in a unique and significantly advantageous manner.
Click below to read more